These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 15791458

  • 1. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative.
    Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, Sausville EA.
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):115-25. PubMed ID: 15791458
    [Abstract] [Full Text] [Related]

  • 2. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM.
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [Abstract] [Full Text] [Related]

  • 3. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
    Glaze ER, Lambert AL, Smith AC, Page JG, Johnson WD, McCormick DL, Brown AP, Levine BS, Covey JM, Egorin MJ, Eiseman JL, Holleran JL, Sausville EA, Tomaszewski JE.
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):637-47. PubMed ID: 15986212
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 5. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
    Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ.
    Clin Cancer Res; 2004 Dec 01; 10(23):8077-84. PubMed ID: 15585643
    [Abstract] [Full Text] [Related]

  • 6. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives.
    Tian ZQ, Liu Y, Zhang D, Wang Z, Dong SD, Carreras CW, Zhou Y, Rastelli G, Santi DV, Myles DC.
    Bioorg Med Chem; 2004 Oct 15; 12(20):5317-29. PubMed ID: 15388159
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
    Kraus-Berthier L, Guilbaud N, Léonce S, Parker T, Genissel P, Guillonneau C, Goldstein S, Atassi G, Pierré A.
    Cancer Chemother Pharmacol; 2002 Aug 15; 50(2):95-103. PubMed ID: 12172972
    [Abstract] [Full Text] [Related]

  • 9. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK.
    Proc Natl Acad Sci U S A; 2006 Nov 14; 103(46):17408-13. PubMed ID: 17090671
    [Abstract] [Full Text] [Related]

  • 10. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
    Yin X, Zhang H, Burrows F, Zhang L, Shores CG.
    Clin Cancer Res; 2005 May 15; 11(10):3889-96. PubMed ID: 15897590
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
    Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, Egorin MJ.
    Cancer Chemother Pharmacol; 2005 Jan 15; 55(1):21-32. PubMed ID: 15338192
    [Abstract] [Full Text] [Related]

  • 12. Anti-tumor effect of N-beta-alanyl-5-S-glutathionyldihydroxyphenylalanine (5-S-GAD), a novel anti-bacterial substance from an insect.
    Akiyama N, Hijikata M, Kobayashi A, Yamori T, Tsuruo T, Natori S.
    Anticancer Res; 2000 Jan 15; 20(1A):357-62. PubMed ID: 10769680
    [Abstract] [Full Text] [Related]

  • 13. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW.
    Cancer Res; 2005 Jun 01; 65(11):4929-38. PubMed ID: 15930315
    [Abstract] [Full Text] [Related]

  • 14. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
    Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, Thillainathan J, Hollingshead M, Sausville EA, Giavazzi R.
    Clin Cancer Res; 2004 Jul 15; 10(14):4813-21. PubMed ID: 15269157
    [Abstract] [Full Text] [Related]

  • 15. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K, Lamphere L, Unteregger G, Jung V, Kaplan F, Xu JP, Rattel B, Caligiuri M.
    Cancer Chemother Pharmacol; 2007 Sep 15; 60(4):589-600. PubMed ID: 17541592
    [Abstract] [Full Text] [Related]

  • 16. An experimental study on the antitumor effect of 131I-17-AAG in vitro and in vivo.
    Wenyong T, Lu L, Daozhen C, Weidong Y, Ying H.
    Ann Nucl Med; 2009 Feb 15; 23(2):113-22. PubMed ID: 19225933
    [Abstract] [Full Text] [Related]

  • 17. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J, Dhani N, Cao MP, Zheng J, Clarkson R, Radulovich N, Navab R, Horn LC, Hedley DW.
    Cancer Res; 2009 Jun 01; 69(11):4750-9. PubMed ID: 19458065
    [Abstract] [Full Text] [Related]

  • 18. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
    Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, Davis ME.
    Clin Cancer Res; 2006 Mar 01; 12(5):1606-14. PubMed ID: 16533788
    [Abstract] [Full Text] [Related]

  • 19. The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo.
    Newcomb EW, Lukyanov Y, Schnee T, Esencay M, Fischer I, Hong D, Shao Y, Zagzag D.
    Anticancer Drugs; 2007 Sep 01; 18(8):875-82. PubMed ID: 17667592
    [Abstract] [Full Text] [Related]

  • 20. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
    Alley MC, Hollingshead MG, Pacula-Cox CM, Waud WR, Hartley JA, Howard PW, Gregson SJ, Thurston DE, Sausville EA.
    Cancer Res; 2004 Sep 15; 64(18):6700-6. PubMed ID: 15374987
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.